Stock HNGZY HANGZHOU TIGERMED CONSULTING CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hangzhou Tigermed Consulting Co., Ltd OTC Markets

Equities

HNGZY

US41044T1088

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 10:13:36 19/12/2023 pm IST 		5-day change 1st Jan Change
4.2 USD -4.55% Intraday chart for Hangzhou Tigermed Consulting Co., Ltd -.--% -.--%
18/06 Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes CI
14/06 Tigermed Consulting Assures Normal Operations Amid Share Price Fluctuations MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 47,335 1,39,718 1,04,196 87,567 44,807 39,295 - -
Enterprise Value (EV) 1 46,226 1,29,700 96,434 82,021 40,354 31,992 31,496 30,157
P/E ratio 55.9 x 73.8 x 38.7 x 45 x 23.5 x 20.7 x 17.2 x 15.1 x
Yield 0.44% 0.19% 0.39% 0.52% 1.03% 1.03% 1.22% 1.24%
Capitalization / Revenue 16.9 x 43.8 x 20 x 12.4 x 6.07 x 4.95 x 4.36 x 3.84 x
EV / Revenue 16.5 x 40.6 x 18.5 x 11.6 x 5.47 x 4.03 x 3.49 x 2.94 x
EV / EBITDA 40.8 x 56.2 x 25.2 x 27.7 x 13.7 x 11.3 x 9.51 x 7.82 x
EV / FCF 108 x 154 x 91.3 x 90 x 47.9 x 20.7 x 14.9 x 19.2 x
FCF Yield 0.93% 0.65% 1.1% 1.11% 2.09% 4.83% 6.7% 5.2%
Price to Book 11.2 x 8.75 x 6.15 x 4.67 x 2.28 x 1.82 x 1.67 x 1.53 x
Nbr of stocks (in thousands) 7,49,557 8,72,509 8,60,729 8,64,949 8,66,366 8,61,497 - -
Reference price 2 63.15 161.6 127.8 104.8 54.97 48.78 48.78 48.78
Announcement Date 28/02/20 29/03/21 10/03/22 28/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,803 3,192 5,214 7,085 7,384 8,106 9,012 10,242
EBITDA 1 1,132 2,308 3,820 2,963 2,949 2,837 3,310 3,856
EBIT 1 1,085 2,222 3,697 2,678 2,610 2,621 3,262 3,721
Operating Margin 38.69% 69.62% 70.91% 37.8% 35.35% 32.34% 36.2% 36.33%
Earnings before Tax (EBT) 1 1,089 2,219 3,690 2,595 2,490 2,539 3,061 2,967
Net income 1 841.6 1,750 2,879 2,016 2,027 2,051 2,467 2,847
Net margin 30.02% 54.81% 55.22% 28.45% 27.44% 25.3% 27.37% 27.79%
EPS 2 1.130 2.190 3.300 2.330 2.340 2.358 2.841 3.229
Free Cash Flow 1 428 842.9 1,057 910.9 842 1,704 2,112 1,569
FCF margin 15.27% 26.4% 20.27% 12.86% 11.4% 21.02% 23.43% 15.32%
FCF Conversion (EBITDA) 37.81% 36.52% 27.66% 30.74% 28.55% 60.05% 63.79% 40.69%
FCF Conversion (Net income) 50.85% 48.17% 36.7% 45.18% 41.55% 83.07% 85.6% 55.11%
Dividend per Share 2 0.2780 0.3000 0.5000 0.5500 0.5680 0.5024 0.5942 0.6041
Announcement Date 28/02/20 29/03/21 10/03/22 28/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,819 1,818 1,776 3,594 1,812 1,679 1,805 1,906 3,711 1,940 1,734 1,660 2,087 2,183 2,272 - -
EBITDA - - - - - - - - - - - - - - - - -
EBIT 1,356 654.4 826.5 906.4 520.1 581.4 418.2 480.8 1,599 713.1 - - - - - - -
Operating Margin 74.57% 36% 46.53% 25.22% 28.71% 34.62% 23.18% 25.22% 43.08% 36.77% - - - - - - -
Earnings before Tax (EBT) 1 1,349 656 823.9 1,480 526.1 588.9 631.1 968.1 1,599 715.3 175.7 - 537.2 637.4 787.1 - -
Net income 1 1,093 518.4 673.6 1,192 412.7 411.4 568.5 819.9 1,388 491.3 146.9 - 417.4 477 633 - -
Net margin 60.11% 28.52% 37.92% 33.16% 22.78% 24.5% 31.5% 43.01% 37.41% 25.33% 8.47% - 20% 21.85% 27.86% - -
EPS 2 1.260 0.6000 0.7800 - 0.4800 0.4700 0.6600 0.9500 - 0.5600 0.1700 0.2700 0.5095 0.5722 0.7085 0.4200 0.5800
Dividend per Share 2 0.5000 - - - - 0.5500 - - - - 0.5680 - - - 0.4040 - -
Announcement Date 10/03/22 26/04/22 25/08/22 25/08/22 25/10/22 28/03/23 25/04/23 25/08/23 25/08/23 27/10/23 28/03/24 25/04/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,109 10,018 7,762 5,546 4,452 6,006 7,800 9,138
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 428 843 1,057 911 842 1,704 2,112 1,569
ROE (net income / shareholders' equity) 23.7% 18.7% 16.8% 10.7% 9.95% 8.08% 8.59% 10.9%
ROA (Net income/ Total Assets) 14.3% 12.9% 13.3% 7.84% 7.09% 5.15% 7.21% 7.77%
Assets 1 5,906 13,519 21,624 25,715 28,564 39,790 34,218 36,631
Book Value Per Share 2 5.640 18.50 20.80 22.40 24.10 26.80 29.30 32.00
Cash Flow per Share 2 0.7000 1.140 1.630 1.560 1.320 2.820 2.390 3.170
Capex 1 99.5 156 367 447 308 699 407 394
Capex / Sales 3.55% 4.88% 7.04% 6.3% 4.18% 8.62% 4.19% 3.54%
Announcement Date 28/02/20 29/03/21 10/03/22 28/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hangzhou Tigermed Consulting Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
48.78 CNY
Average target price
74.23 CNY
Spread / Average Target
+52.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+21.85% 4.64TCr
LONZA GROUP AG Stock Lonza Group AG
+38.37% 3.91TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 3.88TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.04% 3.12TCr
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 2.58TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.65% 2.59TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+38.43% 1.31TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.92% 1.13TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.29% 1.07TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 300347 Stock
  4. HNGZY Stock
  5. Financials Hangzhou Tigermed Consulting Co., Ltd